サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654681

胸水治療の世界市場：2025年～2033年

Global Pleural Effusions Treatment Market - 2025-2033

出版日
ページ情報
英文 146 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
胸水治療の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 146 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胸水治療の世界市場は、2024年に49億米ドルに達し、2033年までには76億米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは5.1％で成長する見込みです。

胸水治療は、胸水（胸膜腔（肺と胸壁の間の領域）に過剰な液体が貯留することを特徴とする状態）の診断、管理、緩和を目的とした医学的アプローチや手技を指します。胸水は、感染症、悪性腫瘍、心不全、肝硬変、その他の全身性疾患や局所性疾患など、さまざまな基礎的原因によって起こる可能性があります。治療は、症状を緩和し、再発を予防し、胸水貯留の根本的な原因に対処することを目的とします。

胸水治療市場は、心不全、がん、感染症、呼吸器疾患など胸水の原因となる疾患の有病率の上昇により、大きな需要が発生しています。この需要を牽引しているのは、胸水とその症状を管理するために効果的な診断・治療介入を必要とする患者の増加です。例えば、米国国立衛生研究所によると、胸水貯留は最も一般的な胸腔疾患であり、米国では年間150万人の患者が罹患しています。このような有病率の上昇が、効果的な治療に対する需要を押し上げています。

市場力学：

促進要因と抑制要因

胸水治療の進歩の高まり

胸水に対する治療法の進歩の高まりは、胸水治療市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられています。これらの進歩には主に、低侵襲手技の開発、新規薬剤の開発、ドレナージ手技の改善、個別化された治療戦略が含まれ、これらすべてが治療効果を高め、患者の転帰を改善し、ヘルスケアコストを削減しています。治療オプションの絶え間ない進化は、ヘルスケア専門家が胸水を効率的に管理することを容易にし、その採用の急増につながっています。

スマートドレナージシステムや高度な呼吸チューブ留置装置が胸水治療において台頭してきており、継続的なモニタリングと自動的な体液回収を可能にしています。これらの装置は、頻繁な臨床介入の必要性を減らし、患者がより快適に胸水を管理できるようにします。

例えば、2023年9月、Qure.aiは、そのAI対応ソリューションqXRについて、2つの重要な所見の下、米国食品医薬品局（FDA）から極めて重要な510（k）クリアランスを取得したと発表しました。Qure社のqXRは今回、気胸（PTX）と胸水（PE）のトリアージに使用できることが承認され、これらは救急治療室や集中治療室（ICU）で深刻な課題となっています。今回の認可は、Qure社の既存のFDA認可製品ポートフォリオである、呼吸チューブ留置用qXR-BT、救急室用頭部CTスキャン用qER、頭部CT定量化ソフトウェアqER-Quantに追加されるものです。

胸水貯留の診断および治療管理で最も一般的な手技は、胸腔穿刺と胸水除去を伴う胸腔穿刺です。これらの進歩により、気胸（肺の虚脱）や感染症などの合併症を最小限に抑えながら、胸水抜去の精度が向上しました。これは胸水の診断と緩和ケアの両方における標準的な治療法となりました。

例えば、2024年1月、Laborie Medical Technologies, Inc.は、患者ケアと医療従事者の生産性向上を目的とした新しい胸水ドレナージ装置、RenovaRP Centesis Systemを発表しました。RenovaRP Centesis Systemは、既存のレノバRPパラセンテシスポンプを改良したもので、胸腔穿刺の適応を拡大し、装置のハンドルとネストを再設計することで、全体的なユーザーエクスペリエンスを向上させています。胸腔穿刺は、腹水や胸水貯留を含む様々な症状に苦しむ患者にとって非常に重要です。

合併症と再発のリスク

胸水の治療は、この病態を管理するために不可欠ですが、しばしば合併症や再発に関する課題に直面し、胸水治療市場全体の成長を妨げる可能性があります。これらの合併症や体液再貯留の高いリスクは、胸水の効果的な管理に大きな障壁をもたらし、患者の転帰とヘルスケア資源の両方に影響を与えます。

胸腔穿刺、経管的胸腔吻合術、胸膜癒着術などの侵襲的治療には、感染、気胸（肺の虚脱）、出血、疼痛などの重篤な合併症を引き起こすリスクが内在しています。このような合併症の可能性は侵襲的治療の魅力を低下させ、侵襲性の低い、または保存的な管理アプローチを好むようになり、高度な胸水治療の必要性を遅らせたり、減らしたりする可能性があります。

再発は、特に根本的な原因が効果的に治療または管理されていない症例において、胸水の管理における主要な課題の1つです。例えば、一般的に肺がん、乳がん、中皮腫に起因する悪性胸水（MPE）の患者は、治療後に胸水貯留を繰り返すことが多いです。

胸膜癒着術は多くの症例で有効ですが、必ずしも意図したとおりに機能するとは限りません。特に、肺が閉じ込められたり、胸膜が肥厚していたり、胸膜疾患が広範囲に及んでいる患者には困難が伴います。悪性胸水の患者にとって、胸膜癒着術は必ずしも永続的な解決策ではありません。腫瘍の進行により胸水が再貯留し、その処置が無効となることがあるからです。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：疾患タイプ別
  • スニペット：治療法別
  • スニペット：用途別
  • スニペット：エンドユーザー別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 胸水に対する治療法の進歩
    • 抑制要因
      • 合併症・再発のリスク
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 胸水治療市場、疾病タイプ別

  • 漏出性胸水
  • 滲出性胸水

第6章 胸水治療市場、治療法別

  • 胸腔穿刺
  • チューブ胸腔造設術
  • 胸膜癒着術
  • 胸膜剥離術
  • 胸膜腹膜シャント
  • カテーテルの配置
  • その他

第7章 胸水治療市場、用途別

  • 悪性胸水
  • 疑似悪性胸水

第8章 胸水治療市場、エンドユーザー別

  • 病院
  • 外来手術センター
  • 専門クリニック
  • 在宅医療
  • その他

第9章 胸水治療市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • B. Braun SE
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Becton, Dickinson and Company
  • Bearpac Medical, LLC.
  • Redax S.p.a.
  • Rocket Medical
  • PFM Medical, Inc.
  • Cook Medical Inc.
  • Boston Medical Products Inc.
  • Pfizer Inc.
  • Grena Limited

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第13章 付録

目次
Product Code: PH5023

The global pleural effusions treatment market reached US$ 4.9 billion in 2024 and is expected to reach US$ 7.6 billion by 2033, growing at a CAGR of 5.1% during the forecast period 2025-2033.

Pleural effusions treatment refers to the medical approaches and procedures aimed at diagnosing, managing and alleviating pleural effusions, a condition characterized by the accumulation of excess fluid in the pleural space (the area between the lungs and the chest wall). Pleural effusions can occur due to a wide range of underlying causes, such as infections, malignancies, heart failure, liver cirrhosis and other systemic or localized diseases. Treatment is designed to relieve symptoms, prevent recurrence and address the underlying cause of the fluid buildup.

The pleural effusions treatment market is experiencing significant demand due to the rising prevalence of conditions that cause pleural effusions, such as heart failure, cancer, infections and respiratory diseases. This demand is driven by an increasing number of patients requiring effective diagnostic and therapeutic interventions to manage pleural effusion and its symptoms. For instance, according to the National Institute of Health, pleural effusion is the most common pleural space disease, affecting 1.5 million patients annually in the United States. These rising prevalence boosts the demand for effective treatment.

Market Dynamics: Drivers & Restraints

Rising therapeutic advancements for pleural effusions

The rising therapeutic advancements for pleural effusions is significantly driving the growth of the pleural effusions treatment market and is expected to drive the market over the forecast period. These advancements primarily include the development of minimally invasive procedures, novel drugs, improved drainage techniques and personalized treatment strategies, all of which have enhanced the effectiveness of treatments, improved patient outcomes and reduced healthcare costs. The continuous evolution of therapeutic options is making it easier for healthcare professionals to manage pleural effusions efficiently, leading to a surge in their adoption.

Smart drainage systems and advanced breathing tube placement devices are emerging in the treatment of pleural effusions, providing continuous monitoring and automatic fluid collection. These devices reduce the need for frequent clinical interventions and enable patients to manage their effusions more comfortably.

For instance, in September 2023, Qure.ai announced a pivotal 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-enabled solution, qXR, under two critical findings. Qure's qXR has now been cleared to triage pneumothorax (PTX) and pleural effusion (PE), which present severe challenges in emergency rooms and intensive care units (ICUs). The newest clearance is an addition to Qure's existing FDA-cleared product portfolio that includes qXR-BT for breathing tube placement, qER for emergency room head CT scans, and qER-Quant for head CT quantification software.

The most common procedures used for diagnostic and therapeutic management of pleural effusion is thoracentesis and paracentesis, which involves the removal of pleural fluid. These advancements improved the accuracy of fluid extraction while minimizing complications such as pneumothorax (collapsed lung) and infection. This has become a standard practice in both diagnostic and palliative care for pleural effusions.

For instance, in January 2024, Laborie Medical Technologies, Inc. has released the RenovaRP Centesis System, a new fluid drainage device meant to enhance patient care and healthcare workers' productivity. The RenovaRP Centesis System improves on the existing RenovaRP paracentesis pump by adding an enlarged indication for thoracentesis and redesigning the device's handle and nest to improve the overall user experience. Paracentesis process is crucial for patients suffering from various conditions, including ascites or pleural effusion.

Risk of complications and recurrence

The treatment of pleural effusions, while essential for managing this condition, often faces challenges related to complications and recurrence, which can hamper the overall growth of the pleural effusions treatment Market. These complications and the high risk of fluid reaccumulation pose significant barriers to the effective management of pleural effusions, impacting both patient outcomes and healthcare resources.

Invasive treatments such as thoracentesis, tube thoracostomy and pleurodesis carry inherent risks that can lead to severe complications, including infection, pneumothorax (collapsed lung), bleeding, and pain. The potential for these complications reduces the attractiveness of invasive treatments, leading to a preference for less invasive or conservative management approaches, which could delay or reduce the need for advanced pleural effusion therapies.

Recurrence is one of the major challenges in managing pleural effusions, especially in cases where the underlying cause is not effectively treated or managed. For instance, patients with malignant pleural effusions (MPEs), commonly resulting from lung cancer, breast cancer or mesothelioma, often experience repeated fluid buildup after treatment.

Pleurodesis, although effective in many cases, does not always work as intended. It is particularly challenging in patients with trapped lung, thickened pleura or extensive pleural disease. For patients with malignant pleural effusions, pleurodesis is not always a permanent solution, as tumor progression can lead to fluid reaccumulation, rendering the procedure ineffective.

Segment Analysis

The global pleural effusions treatment market is segmented based on disease type, treatment modality, application, end-user and region.

Disease Type:

The exudative pleural effusions segment is expected to dominate the global pleural effusions treatment market share

Exudative pleural effusions represent a key segment within the pleural effusions treatment market, contributing significantly to its growth. Exudative effusions occur when there is inflammation or injury to the pleura, leading to the leakage of proteins, cells, and other substances into the pleural space. This type of effusion is typically associated with conditions such as lung cancer, pneumonia, tuberculosis and heart failure, among others.

Exudative pleural effusions is a most common than transudative pleural effusions, which drives the segment demand for effective treatment. For instance, according to the European Respiratory Society, pleural effusion affects up to 1.5 million people in the United States annually. In this one third of pleural effusions are exudative effusions. Malignant Pleural Effusions (MPE) affects 1,50,000 patients in the United States and 50,000 in the UK each year. In Europe, 100,000 effusions occur each year due to lung cancer alone.

Exudative pleural effusions require more aggressive treatment approaches, especially when caused by malignancy or infection. These treatments often involve thoracentesis, pleurodesis, and indwelling pleural catheters (IPCs). The complexity of managing exudative effusions, particularly in patients with cancer or tuberculosis, has led to the continued demand for effective treatment solutions.

Geographical Analysis

North America is expected to hold a significant position in the global pleural effusions treatment market share

The high incidence of diseases like lung cancer, breast cancer, heart failure, and pneumonia in North America is a major driver of pleural effusion cases. Exudative pleural effusions, which are commonly caused by these conditions, are particularly prevalent in the region. According to the National Institute of Health (NIH), Pleural effusion affects around 1.5 million individuals in the United States each year. Malignant Pleural Effusions (MPE) affects 150,000 people in the United States. These high malignant pleural effusions burden significantly contributes to the demand for pleural effusion treatments in the region.

There is a high level of awareness regarding pleural effusions and related conditions among healthcare professionals and the general population in North America. This awareness has led to early diagnosis and better access to specialized care, further driving the demand for pleural effusion treatments. For instance, in the U.S., patients often benefit from multidisciplinary treatment approaches involving oncologists, pulmonologists, and cardiologists for conditions that cause pleural effusions, such as lung cancer and heart failure. This holistic approach improves outcomes and drives the need for ongoing therapies, especially for recurrent malignant pleural effusions (MPEs).

Asia Pacific is growing at the fastest pace in the global pleural effusions treatment market share

The increasing adoption of minimally invasive treatments such as thoracentesis, pleurodesis, and indwelling pleural catheters (IPCs) is helping to expand the pleural effusion treatment market in Asia-Pacific. These procedures are not only less risky but also offer faster recovery times, which increases patient acceptance and healthcare providers' adoption. For instance, China has witnessed a rise in the use of ultrasound-guided thoracentesis for the diagnosis and management of pleural effusions, which is safer and more efficient than traditional methods. The increasing use of pleurodesis for malignant effusions is also contributing to the region's market growth.

Public health awareness campaigns and better access to diagnostic services have played a significant role in increasing the diagnosis rates of pleural effusions in the APAC region. Early detection of pleural effusions, particularly those associated with lung cancer or tuberculosis, allows for better management and improved patient outcomes. For instance, in Japan, the National Cancer Center provides lung cancer screening programs that help in the early diagnosis of lung cancer and its associated pleural effusions, which has increased demand for pleural effusion treatments.

Competitive Landscape

The major global players in the pleural effusions treatment market include B. Braun SE, Becton, Dickinson and Company, Bearpac Medical, LLC., Redax S.p.a., Rocket Medical, PFM Medical, Inc., Cook Medical Inc., Boston Medical Products Inc., Pfizer Inc., Grena Limited and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Pleural Effusions Treatment market report delivers a detailed analysis with 70 key tables, more than 66 visually impactful figures, and 146 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Disease Type
  • 2.4. Snippet by Treatment Modality
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Therapeutic Advancements for Pleural Effusions
    • 3.1.2. Restraints
      • 3.1.2.1. Risk of Complications and Recurrence
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics

5. Pleural Effusions Treatment Market, By Disease Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 5.1.2. Market Attractiveness Index, By Disease Type
  • 5.2. Transudative Pleural Effusions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Exudative Pleural Effusions

6. Pleural Effusions Treatment Market, By Treatment Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 6.1.2. Market Attractiveness Index, By Treatment Modality
  • 6.2. Thoracentesis*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Tube Thoracostomy
  • 6.4. Pleurodesis
  • 6.5. Pleural Decortication
  • 6.6. Pleuroperitoneal Shunt
  • 6.7. Catheter Placement
  • 6.8. Others

7. Pleural Effusions Treatment Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Malignant Pleural Effusions*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Paramalignant Pleural Effusions

8. Pleural Effusions Treatment Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgery Centers
  • 8.4. Specialty Clinics
  • 8.5. Homecare Settings
  • 8.6. Others

9. Pleural Effusions Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. B. Braun SE*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Becton, Dickinson and Company
  • 11.3. Bearpac Medical, LLC.
  • 11.4. Redax S.p.a.
  • 11.5. Rocket Medical
  • 11.6. PFM Medical, Inc.
  • 11.7. Cook Medical Inc.
  • 11.8. Boston Medical Products Inc.
  • 11.9. Pfizer Inc.
  • 11.10. Grena Limited

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us